SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel (INTC) is trending following a mixed earnings report and cautious forward guidance, leading to a significant pullback. While many in the community debate high valuation metrics and ongoing competition with peers like NVDA and AMD, others remain optimistic, emphasizing the company's strategic importance in the US semiconductor manufacturing push and temporary supply constraints as a "high-class problem."

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune (ALT) is commanding attention as its Breakthrough Therapy Designation for pemvidutide in MASH and obesity ignites intense community speculation around a potential buyout or strategic partnership. With significant short interest, many investors are actively discussing the possibility of a major rerating or acquisition by a pharmaceutical giant, viewing the stock as currently undervalued within the thriving GLP-1 sector.

RYVYL Inc. is a financial technology company that develops software platforms and tools that are focused on providing global payment acceptance and disbursement capabilities. It offers an innovative payment platform-as-a-service that redefines global payment solutions, enabling seamless business-to-business, consumer-to-business, and peer-to-peer transactions worldwide. The company leverages advanced electronic payment technology to deliver seamless financial solutions across global markets. It operates through two geographical segments: North America and International. The company was founded on April 10, 2007 and is headquartered in San Diego, CA.

Ryvyl Inc

Ryvyl (RVYL) is trending as its merger with Roundtable/RTB Digital advances, highlighted by recent S-4 filings and progress toward NASDAQ compliance, including a significant strategic partnership for Roundtable. The community is actively discussing a potential short squeeze, driven by the stock's exceptionally low public float and perceived undervaluation, anticipating substantial upside from the combined entity's Web3 digital media platform and Bitcoin treasury elements.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing significant trending activity following reports of robust early prescription data for its new oral weight-loss medication, which the community views as a substantial market advantage. Investors are highly optimistic about the company's position as a leader in the expanding oral GLP-1 sector, anticipating a re-evaluation of its valuation amid strong demand.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as the community eagerly discusses the finalized deal for a US joint venture involving TikTok, where Oracle plays a pivotal role in cloud infrastructure and security. Many anticipate this could drive significant new revenue and solidify Oracle's standing in the AI and sovereign cloud sectors, though some maintain caution regarding the broader impact on its valuation and existing debt.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano is currently experiencing a significant surge following news of its all-stock merger with AI cloud computing firm Corvex, which also announced a long-term NVIDIA H200 GPU deployment. This has ignited strong community discussion, with many anticipating a short squeeze and parabolic price movement due to the stock's notably low float. However, some traders are urging caution, highlighting that the NVIDIA news relates to GPU usage rather than a direct partnership and pointing to potential dilution.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corporation is trending due to anticipation surrounding upcoming regulatory decisions for its inhaled insulin Afrezza, including a label update and pediatric approval, alongside strong quarterly revenue performance. Community discussion centers on the potential for increased market penetration and significant pipeline advancements, with many speculating about future collaborations or a potential acquisition given the value of its Technosphere platform and expanding product offerings.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending following a significant memorandum of understanding with the Government of Gujarat and Kaynes SemiCon for India's first secure semiconductor center focused on post-quantum cryptography. The community is actively discussing this strategic collaboration and the broader implications of quantum-resistant security, anticipating substantial growth and potential short squeeze activity as the sector converges with AI and other advanced technologies.

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

60 Degrees Pharmaceuticals Inc

SXTP is currently trending due to its announced partnership with Runway Health, which will expand access to its malaria prevention drug, ARAKODA, via a telehealth platform. This news, coupled with the stock's low float and recent reverse split, is fueling intense community discussion about its potential for a short squeeze and sustained upward momentum. While many traders are celebrating significant gains, some express caution regarding the stock's volatility and the possibility of future dilution.

Movement Network is a secure and scalable blockchain designed to make Move programming accessible to developers everywhere. With high-performance execution and security, Movement delivers the infrastructure for the next generation of decentralized applications and unleashes opportunity and financial empowerment for anyone, anywhere.  $MOVE is the native token of Movement Network, for transaction fees and staking to secure the network. The Movement M1 (Layer 1) Network is powered by the Move programming language, unleashing opportunity, accessibility, and financial empowerment for anyone, anywhere.

MarketMove

MarketMove is trending due to the planned all-stock merger between Movano and Corvex, with Corvex recently announcing a significant long-term NVIDIA H200 GPU deployment for an AI-driven battery technology provider. The community is actively discussing the implications of this move into AI infrastructure, with high volatility and speculation around short squeeze potential driving conversation, despite some concerns regarding the merger's terms for existing shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Biotech Stocks To Add to Your Watchlist - January 20th

ImmunityBio, Danaher, Moderna, argenex, Vertex Pharmaceuticals, Abivax, and Recursion Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 25.0% in December

Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest...

Abivax (NASDAQ:ABVX) Stock Price Down 6.1% - Here's Why

Abivax (NASDAQ:ABVX) Trading Down 6.1% - Here's What Happened...

Best Biotech Stocks To Keep An Eye On - January 15th

Abivax, Moderna, Danaher, ImmunityBio, argenex, Vertex Pharmaceuticals, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Abivax's Options: A Look at What the Big Money is Thinking

Biotech Stocks To Consider - January 12th

Cidara Therapeutics, Abivax, and Danaher are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that...

Abivax (NASDAQ:ABVX) Sees Large Volume Increase Following Analyst Upgrade

Abivax (NASDAQ:ABVX) Sees Large Volume Increase on Analyst Upgrade...

<ul class="summary-bullets"><li>Eli Lilly has not yet submitted a formal bid for Abivax.</li><li>In an interview with Bloomberg, Abivax CEO Marc de Garidel stated that a Treasury review is necessary in France and typically takes up to three months.</li><li>Garidel added that major pharma companies can no longer ignore Abivax’s experimental drug for inflammatory bowel disease, obefazimod.</li></ul>Abivax SA’s (ABVX) American Depository Receipts (ADRs) soared more than 32% in Monday’s pre-market trade after reports stated that U.S. pharmaceutical giant Eli Lilly &amp; Co. (LLY) is interested in acquiring the French biotechnology company.According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.lalettre.fr/fr/entreprises_sante/2026/01/12/eli-lilly-pret-a-mettre-15-milliards-d-euros-sur-la-table-pour-la-biotech-abivax,110595898-eve">report</a> by La Lettre on Monday, Eli Lilly is said to be ready to acquire Abivax for €15 billion ($17.5 billion), which is nearly twice the current market capitalization of the French biotech company.Retail sentiment on Stocktwits about Abivax SA was in the ‘bullish’ territory, with the ticker among the top 10 trending symbols on the platform at the time of writing.<a href="https://stocktwits.com/symbol/ABVX">Eli Lilly shares</a> were up nearly 1% in Monday’s pre-market trade.<h2 class="st-heading-2">Eli Lilly’s Interest In Abivax</h2>The report added that Eli Lilly is awaiting guidance from France’s Finance Ministry to understand if an acquisition of Abivax would be subject to foreign investment controls.Eli Lilly has not yet submitted a formal bid for Abivax. In an&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-12/abivax-ceo-says-big-pharma-can-t-ignore-its-experimental-drug">interview</a> with Bloomberg, Abivax CEO Marc de Garidel stated that a Treasury review is necessary in France and typically takes up to three months.<h2 class="st-heading-2">Abivax’ Experimental Drug</h2>Garidel added that major pharma companies can no longer ignore Abivax’s experimental drug for inflammatory bowel disease, obefazimod.“If you are Big Pharma, you cannot ignore that this product may be one of the most-used products in the next decade,” he added in the interview.In a separate&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.biotechtv.com/post/marc-de-garidel-abivax-january-11-2026">interview</a> with BiotechTV, Garidel stated that Abivax is focusing on developing the drug and bringing it to the market, while adding that he has no control over the rumors and speculation surrounding the company.<h2 class="st-heading-2">Price Target Hikes Pour In</h2>Analysts at Morgan Stanley and BTIG hiked their price targets for Abivax, according to TheFly. Morgan Stanley hiked its price target for ABVX to $145 from $101, while maintaining its ‘Overweight’ rating on the stock.Analysts at BTIG hiked their price target to $150 from $120, while keeping a ‘Buy’ rating on Abivax shares.Both firms cited optimism around Abivax’s obefazimod, with Morgan Stanley analysts stating that experts are increasingly encouraged by both the magnitude of effect and tolerability profile demonstrated in the induction portion of the Phase 3 program.<a href="https://stocktwits.com/symbol/ABVX">ABVX ADR</a> is down 17% year-to-date, but up 1,693% over the past 12 months.&nbsp;<a href="https://stocktwits.com/symbol/ABVX">LLY stock</a> is down 1% YTD, but up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/xom-stock-declines-after-trump-threatens-sidelining-exxon-mobil-venezuela/cmU9wSrR43D">XOM Stock Falls Pre-Market After Trump Reportedly Signals Venezuela Exclusion – Retail Sentiment Sours</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen

ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest

Eli Lilly is awaiting guidance from France’s Finance Ministry to understand if an acquisition of Abivax would be subject to foreign investment controls.

Equity

Biotech Stocks Worth Watching - January 8th

Cidara Therapeutics, Abivax, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded...

Abivax (NASDAQ:ABVX) Shares Down 8.7% - Here's Why

Abivax (NASDAQ:ABVX) Shares Down 8.7% - Here's Why...

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

What&#39;s the biggest driver of market volatility right now?

Stocktwits

What's the biggest driver of market volatility right now?

ABVX
Abivax - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ABVX News

ABVXAbivax - ADR